

# **Curriculum vitae - Eleonora Toffoletti**

Eleonora Toffoletti

Born in Udine, Italy, 19.07.1980

e-mail: [eleonora.toffoletti@uniud.it](mailto:eleonora.toffoletti@uniud.it)

## *Current position:*

- since 02/11/2010 - Researcher at Udine University, Department of Medical Sciences, SSD MED15;
- since 01/12/2013 - Physician at Hematology Division of Udine -ASUFC;
- Head of Molecular Diagnostic of oncohematologic diseases at Hematological Division of Udine.

## *Previously*

- Attending doctor at Hematological Division of Udine since 01/12/2009.
- Project collaboration at Hematological Division San Raffaele - Milan, and Immunogenetics Laboratory (prof. Katharina Fleischhauer).

## *Education and training*

- Specialization in Hematology, at the University of Udine, Italy on November 4<sup>th</sup> 2009, summa cum laude.
- Medicine and Surgery degree, University of Udine on October 19<sup>th</sup> 2005, 110/110.

## *Grant*

- Principal Investigator of PRIN2022 Project: "Myelodysplasia-related molecular abnormalities and Clonal Hematopoiesis in patients with relapsed-refractory Lymphoid Malignancies receiving Chimeric Antigen Receptor (CAR) T cells".
- Selected among the 60 best Italian works as Candidate for the Final Contest of the "Under40 in hematology 2013" project.
- Fellowship AIL Udine, (2009-2010).

## *Research activities and collaborations:*

- Member of GIMEMA LabNet CML since 2013 for Udine Hematological Division Laboratory for Minimal Residual Disease harmonization.
- Member of GIMEMA LabNet AML since 2020 for Udine Hematological Division Laboratory for AML molecular characterization.
- Member of CAMPUS ALL for Udine Hematological Division Laboratory for p190 analysis harmonization.
- Head of experimental activities of regional project LAMlabFVG "Creazione di una rete di Laboratori per la Diagnostica Molecolare Avanzata e la Ricerca sulle Leucemie Acute Mieloidi, come Centro di Riferimento per il Triveneto."
- Management of profit/no profit clinical trials studies in oncology in compliance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP) and the applicable regulatory requirement.

## *Teaching activities*

- Professor at Hematology Specialization School – Udine University SSD MED/15 since 2011.
- Tutor/correlator of several graduate theses in: Biotechnology, healthcare laboratory Technicians, Specialization in Hematology, PhD in Healthcare and Diet at Udine University.

*Recent publications of scientific relevance*

ORCID ID: <https://orcid.org/0000-0003-0040-7938>

1. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Candoni A, De Marchi F, Zanini F, Zannier ME, Simeone E, **Toffoletti E**, Chiarvesio A, Cerno M, Fili C, Patriarca F, Fanin R. *Exp Hematol.* 2017 May;49:25-33
2. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories. Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zocomo S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, **Toffoletti E**, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G. *Oncotarget.* 2017 May 16;8(20):32608-32617.
3. Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia. Raffaella F, Kuzelicki NK, Sorio C, **Toffoletti E**, Montecchini O, Poropat A, Rabusin M, Curci D, Paladin D, Stocco G, Decorti G. *Curr Med Chem.* 2017 Jul 27. doi: 10.2174/0929867324666170727101932. [Epub ahead of print]
4. Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor. Cattina F, Bernardi S, Mantovani V, **Toffoletti E**, Santoro A, Pastore D, Martino B, Console G, Martinelli G, Malagola M. *Hematol Rep.* 2017 Sep 26;9(3):7051
5. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Candoni A, De Marchi F, Zannier ME, Lazzarotto D, Filì C, Dubbini MV, Rabassi N, **Toffoletti E**, Lau BW, Fanin R. *Leuk Res.* 2017 Dec;63:22-27
6. Expression and modulation of S100A4 protein by human mast cells. Domenis R, Pilutti D, Orsaria M, Marzinotto S, Candotti V, Bosisio G, Bulfoni M, Ruaro ME, Di Loreto C, Mea VD, **Toffoletti E**, Lonero AP, Mariuzzi L, Gri G. *Cell Immunol.* 2018 Oct;332:85-93.
7. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi L, **Toffoletti E**, Deambrogi C, Stagno F, Bergamaschi M, Franceschini L, Abruzzese E, Divona MD, Gobbi M, Di Raimondo F, Gaidano G, Tiribelli M, Bonifacio M, Cattaneo C, Iurlo A, Russo D. *Cancer Med.* 2019 May;8(5):2041-2055.
8. WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant. Sperotto A, Gottardi M, Candoni A, **Toffoletti E**, De Marchi R, Petruzzellis G, Pizzano U, Fanin R. *Leuk Res.* 2021 Sep;108:106587.
9. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC". Di Giusto S, **Toffoletti E**, Bonifacio M, Binotto G, Miggiano MC, Calistri E, Stulle M, Ermacora A, Stella R, Scaffidi L, D'Amore F, Scotton G, Griguolo D, De Matteis G, Bertorelle R, Krampera M, Semenzato G, Fanin R, Damiani D, Tiribelli M. *Cancer Med.* 2023 Feb;12(3):3180-3184.

10. Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia. Tiribelli M, **Toffoletti E**, Di Giusto S, Fanin R, Damiani D. Eur J Haematol. 2023 Mar;110(3):330-331.

I give the authorization for the treatment of my personal data according to Italian Law D. Lgs. 196/2003 and Regulation (EU) 2016/679.

Udine, 20/01/2023

dott.ssa Eleonora Toffoletti

